Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Purdue Pharma and AnaBios are planning to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel compounds for the treatment of chronic pain.
Subscribe to our email newsletter
The joint research and development effort would leverage Purdue Pharma’s intellectual property and lead compounds, combined with AnaBios’ Phase-X technology.
Purdue Pharma has more than 10 years of research history in the sodium channel field that led to multiple patent applications and numerous lead compounds targeting Nav1.7 as well as other sodium channel isoforms that are potentially useful for the treatment of chronic pain. Purdue Pharma also has extensive clinical development experience in advancing new drugs for treating pain.
AnaBios is an innovative drug discovery company employing its proprietary Phase-X technology to enable the discovery of novel drugs directly in human tissues, bypassing animal experimentation.
AnaBios generates highly valuable and predictive human data that ensure the selection of the most effective and safest drugs before investing in expensive and time consuming clinical trials. AnaBios has established a unique and unprecedented capability for studying the human peripheral pain pathway in the laboratory, therefore enabling the identification of novel analgesic drugs with potential efficacy in humans.
Purdue Pharma president and CEO Mark Timney said: "The prospect of combining AnaBios’ unique platform and Purdue Pharma’s top quality chemistry exemplifies the powerful nexus of technology-based discovery and industry collaboration.
"This creative partnership fits in well with our strategic plan to continue development of our existing therapeutic programs and ultimately bring value to patients suffering from pain and to healthcare providers."
AnaBios CEO Andre Ghetti said: "We are very excited to have the opportunity to employ AnaBios’ Phase-X® technology to optimize the selection of clinical candidates from the advanced leads that Purdue Pharma has generated.
"Employing human sensory neurons to match the selectivity and properties of sodium channel blockers with specific pain indications, we will maximize the potential success of clinical development of much needed new pain therapeutics."